Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017

S. Homma (Tokyo, Japan)

Source: International Congress 2017 – IPF: from the bench to the bedside
Session: IPF: from the bench to the bedside
Session type: Thematic Poster
Number: 3806
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Homma (Tokyo, Japan). Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017. 3806

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines
Source: Eur Respir Rev 2014; 23:193-214
Year: 2014



Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013

Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice
Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease
Year: 2009

Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP)
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016


Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015



Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013


Registry of idiopathic pulmonary fibrosis patients
Source: International Congress 2016 – Russia Session
Year: 2016

The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF
Source: Eur Respir J 2015; 46: 883-886
Year: 2015


Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013

IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015


Central European idiopathic pulmonary fibrosis (IPF) patients survey
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019

Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation
Source: Eur Respir J, 55 (4) 1901760; 10.1183/13993003.01760-2019
Year: 2020



Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 163-168
Year: 2013



Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016


The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016

Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015